{"id":"NCT03605680","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder","officialTitle":"A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-16","primaryCompletion":"2020-04-11","completion":"2020-04-11","firstPosted":"2018-07-30","resultsPosted":"2021-05-05","lastUpdate":"2022-03-15"},"enrollment":604,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Disorder","Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Centanafadine SR","otherNames":["EB-1020"]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Centanafadine SR","otherNames":["EB-1020"]}],"arms":[{"label":"Single-blind Run-in Period: Placebo","type":"EXPERIMENTAL"},{"label":"Double-blind Treatment Period: Centanafadine SR 200 mg","type":"EXPERIMENTAL"},{"label":"Double-blind Treatment Period: Centanafadine SR 400 mg","type":"EXPERIMENTAL"},{"label":"Double-blind Treatment Period: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD). Participants will either receive a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.","primaryOutcome":{"measure":"Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)","timeFrame":"Baseline and Day 42","effectByArm":[{"arm":"Double-blind Treatment Period: Centanafadine SR 200 mg","deltaMin":-10.1,"sd":0.99},{"arm":"Double-blind Treatment Period: Centanafadine SR 400 mg","deltaMin":-9.73,"sd":0.98},{"arm":"Double-blind Treatment Period: Placebo","deltaMin":-6.98,"sd":0.98}],"pValues":[{"comp":"OG000 vs OG002","p":"=0.0193"},{"comp":"OG001 vs OG002","p":"=0.0392"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":138},"commonTop":["Headache","Decreased appetite","Dry Mouth","Upper respiratory tract infection"]}}